On September 3, 2019 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, reported that senior management will participate in three investor conferences in September, including Citi’s 14th Annual Biotech Conference, H.C. Wainwright 21st Annual Global Investment Conference and Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies (Press release, CymaBay Therapeutics, SEP 3, 2019, View Source [SID1234539188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5
Time: 12:45pm Eastern Time
Format: Panel: Living it Up with the Liver Disease Players – Views on NASH, PBC, etc.
Webcast: View Source

H.C. Wainwright 21st Annual Global Investment Conference
Date: Tuesday, September 10
Time: 9:10am Eastern Time
Format: Corporate Presentation
Webcast: View Source

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Date: Tuesday, September 24
Time: 8:00 am Eastern Time
Format: 1:1 Meetings Only